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Abstract
Background: The safety of revascularization deferral according to pressure wire examination in pa-
tients with chronic kidney disease (CKD) has not been fully established.
Methods: From a retrospective cohort of 439 patients in whom revascularization was deferred after 
physiological assessment, we examined the incidence of patient-oriented composite endpoint (POCE: 
all-cause death, myocardial infarction [MI] and unplanned revascularization) in patients with CKD 
(estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) and without it. 
Results: At 4 years of follow-up, the primary endpoint was met by 25.0% of patients with CKD and 
by 14.4% of patients without CKD (hazard ratio [HR] 1.56, 95% confidence interval [CI] 0.96–2.53,  
p = 0.071). The incidence of POCE was even higher in patients with an eGFR < 30 mL/min/1.73 m2: 
43.8% (HR 3.10, 95% CI 1.08–8.92, p = 0.036). However, no differences were observed in the incidence 
of MI (4.2% vs. 4.4% in non-CKD), target vessel revascularization (5.8% vs. 5.9%), and target vessel 
MI (0.8% vs. 4.6%).
Conclusions: Patients with CKD in whom pressure-wire evaluation led to deferral of coronary re-
vascularization develop more POCE in the long term, compared to patients with normal renal func-
tion. However, the increase in POCE in patients with CKD was seldom related to deferred vessels, 
thus suggesting an epiphenomenon of an intrinsically higher cardiovascular risk of CKD patients.  
(Cardiol J)
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chronic kidney disease
Introduction
Physiological evaluation of coronary stenosis 
is a valuable tool to guide myocardial revasculari-
zation. Its safety has been widely demonstrated in 
the past years [1], shifting the process of treating 
coronary lesions from anatomical to physiological 
grounds. For more than two decades fractional flow 
reserve (FFR) was the only pressure-derived index 
available for functional stenosis assessment. More 
recently, instantaneous wave-free ratio (iFR), a non-
-hyperemic diastolic pressure ratio that overcomes 
some limitations of FFR [2, 3], was demonstrated to 
be non-inferior to FFR in clinical decision-making, 
contributing to more widespread use of pressure 
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One of the ways that pressure guidewire 
interrogation contributes to improved patient 
outcome is by avoiding unneeded revascularization 
procedures in functionally non-significant coronary 
stenoses. While the overall safety of myocardial re-
vascularization deferral based on FFR and iFR has 
been well stablished [5, 6], there is a paucity of data 
regarding such an approach in subgroups of patients 
with high risk of coronary disease progression. One 
such subgroup is made up of patients with chronic 
kidney disease (CKD), which is associated with 
a higher burden of coronary atherosclerosis [7], 
faster disease progression [8], and higher incidence 
of cardiovascular events, compared with patients 
with normal renal function [9, 10]. 
The main aim of this study was to investigate 
whether deferral of coronary stenosis revasculari-
zation based on pressure guidewire interrogation is 
equally safe in patients with CKD and in patients 
with normal function. Additionally, we also wanted 
to investigate the long-term outcomes of revascu-
larization deferral based on FFR or iFR in patients 
with and without CKD. 
Methods
Study design and population selection
This is a single-center, retrospective study 
that collected all consecutive patients who under-
went pressure-wire evaluation of angiographical 
stenosis (by visual estimation), and in whom 
treatment was deferred based on the result of this 
technique. Either FFR or iFR were performed, 
and patients were classified as FFR-deferred or 
iFR-deferred according to the method of pressure 
wire used for evaluation. 
Different baseline characteristics were as-
sessed. Serum creatinine was determined from 
blood samples in the 48 hours prior to the pro-
cedure. The estimated glomerular filtration rate 
(eGFR) was derived using the CKD-EPI formula. 
The cut-off value of 60 mL/min/1.73 m2 was used to 
establish the presence or absence of CKD. Current 
clinical practice guidelines were used to define the 
different CKD stages [11]. 
Procedural aspects
Pressure wire assessment was performed with 
commercial guidewires available during the study 
period — Verrata (Phillips Healthcare, San Diego, 
California) and PressureWire X (St. Jude Medical, 
St. Paul, Minnesota) — and a standard technique 
as previously reported. An intracoronary bolus of 
nitrates (200 µg) was administered before FFR 
or iFR measurement. In cases in which FFR was 
performed, intravenous adenosine was infused with 
a rate of 140 µg/kg/min. At the end of each proce-
dure, the presence of significant drift was ruled-out 
by placing the sensor of the pressure-wire at the 
tip of the guiding catheter.
In patients with stable angina, physiological 
evaluation was performed in the same procedure 
and all intermediate stenoses could be assessed. 
Serial stenoses were assessed as a single lesion and 
only those with non-ischemic values of pressure 
wire examination were deemed for inclusion in the 
present analysis. In patients with acute coronary 
syndromes, interrogation with a pressure wire was 
performed at a staged procedure only in non-culprit 
vessels. The cut-off points to defer revasculariza-
tion were FFR > 0.80 or iFR > 0.89. 
Endpoints
The primary endpoint was the combination 
of all-cause death, myocardial infarction (MI), or 
unplanned revascularization. Secondary endpoints 
were all-cause death, death due to cardiovascular 
causes, MI, and unplanned revascularization. 
Moreover, vessel-related endpoints such as tar-
get vessel MI and target vessel revascularization 
(TVR) were pre-specified as secondary endpoints. 
The minimum follow-up period was 2 years. 
Statistical analysis
The population was divided based on the 
presence or absence of CKD, and the technique of 
pressure wire was used to defer revascularization 
(FFR or iFR). 
Univariate analysis for baseline characteristics 
was done using the Pearson c2 test or Fisher’s exact 
test for categorical variables, as appropriate. Com-
parison between continuous data was made using 
the Student-Fisher t-test or Wilcoxon’s rank test 
in cases of non-normal distributions.
For the primary and secondary endpoints, 
a time-to-event analysis was performed using the 
Cox’s proportional hazards model. Results are 
reported as hazard ratios (HR) with two-sided 
95% confidence intervals (CI). Analyses were 
performed in an unadjusted manner as well as 
being adjusted by variables that were considered 
relevant: age, sex, the presence of diabetes mel-
litus, hypertension, tobacco use, clinical presenta-
tion, and the percentage of angiographic diameter 
stenosis.
The validity of the proportional hazards as-
sumption was assessed using Schoenfeld residuals. 
No signs of violation of the proportional hazards 
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principle were found. Finally, cumulative hazards 
curves were created using the Kaplan-Meier 
method.  
All statistical calculations were carried out 
with STATA 14 (StataCorp. 4905 Lakeway Drive. 
College Station, Texas. USA). 
Results
Study population
From January 2012 to December 2016, 
a total of 1321 vessels underwent pressure-wire 
evaluation. From them, a total of 593 vessels (444 
patients) were deferred according to the result of 
the pressure wire assessment. Five patients were 
excluded because of the unavailability of renal 
function data. A final cohort of 439 patients was 
included in the analysis (Fig. 1).
Baseline characteristics
Of the overall population, 120 (27.3%) patients 
had an eGFR of less than 60 mL/min/1.73 m2. Six-
teen of them (3.6%) had severe eGFR impairment 
(< 30 mL/min/1.73 m2 or hemodialysis). Baseline 
characteristics are shown in Table 1.
Patients with eGFR < 60 mL/min/1.73 m2 
were significantly older (73.5 years vs. 66.6 years, 
p < 0.001) and had a higher prevalence of cardio-
vascular risk factors such as hypertension (79.2% 
vs. 69.9%, p = 0.053), diabetes mellitus (50.8% vs. 
31.7%, p < 0.001), and peripheral vascular disease 
(16.7% vs. 5.6%, p < 0.001). They had higher rates 
of anticoagulation treatment (16.7% vs. 6.3%, 
p = 0.003) and less use of acetylsalicylic acid (ASA; 
89.1% vs. 95.8%, p = 0.008). 
Baseline angiographical characteristics and 
physiological results are shown in Table 2. Patients 
had a mean of 1.3 vessels interrogated in both 
groups. No differences were found in the mean 
values of FFR or iFR in either group, or in the type 
of vessel evaluated, the left anterior descendant 
(LAD) being the most frequently assessed. A less 
than 1% but statistically significant difference was 
seen in the percentage of angiographic stenosis 
(61.0% vs. 59.1%, p = 0.027), but this small dis-
parity can be considered as clinically not relevant.
Figure 1. Flowchart of the study; CABG – coronary artery bypass grafting; FFR — fractional flow reserve; iFR — in-
stantaneous wave-free ratio; eGFR — estimated glomerular filtration rate; PCI — percutaneous coronary intervention.
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2eGFR > 60 mL/min/1.73 m
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Deferred by FFR
n = 94 (78.3%)
Deferred by iFR
n = 68 (21.3%)
Deferred by iFR
n = 26 (21.7%)
2eGFR < 60 mL/min/1.73 m
n = 120 (27.33%)
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Outcomes in patients with and without CKD
The median follow-up was 42.1 (interquartile 
range [IQR] 26.6) and 43.0 (IQR 26.2) months in 
patients with and without CKD, respectively. 
At 4 years, 30 (25.0%) patients with eGFR 
< 60 mL/min/1.73 m2 met the primary endpoint 
(patient-oriented composite endpoint [POCE]: 
composite of all-cause death, MI, or unplanned 
revascularization), in comparison with 46 (14.4%) 
patients with eGFR > 60 mL/min/1.73 m2 (Fig. 2A). 
The unadjusted HR was 1.81 (95% CI 1.15–2.84; 
p = 0.010). This difference was mainly driven 
by a higher rate of all-cause death (13.3% vs. 
5.3%; p = 0.006) and cardiovascular death (5.8% 
vs. 1.3%; p = 0.012), and a less prominent but 
also higher rate of unplanned revascularization 
in patients with worse renal function (11.7% vs. 
7.2%; p = 0.097; Table 3). No differences were 
observed in the incidence of MI (4.2% vs. 4.4%; 
p = 0.967). The adjusted multivariate analysis 
failed to reach statistical significance for the pri-
mary or the secondary endpoints but showed 
a trend towards a higher incidence of POCE in pa-
tients with eGFR < 60 mL/min/1.73 m2, with a HR 
of 1.56 (95% CI 0.96–2.53; p = 0.071), and towards 
more frequent unplanned revascularizations (HR 
1.91; 95% CI 0.93–3.93; p = 0.078).
Nevertheless, in the categorical analysis of the 
stages of CKD, the patients from stages G4 and G5 
(eGFR of less than 30 mL/min/1.73 m2) showed 
a marked increase in the incidence of POCE when 
compared to the reference category (stage G1: 
eGFR > 60 mL/min/1.73 m2). In this case, the 
association remained significant in the adjusted 
analysis, with a HR of 3.10 (95% CI 1.08–8.92; 
p = 0.036; Table 4, Fig. 2B).
Interestingly, the higher event rate observed in 
patients with CKD was not related with the vessel 
Table 1. Baseline characteristics. 
No CKD (eGFR > 60 mL/ 
/min/1.73 m2)
CKD (eGFR < 60 mL/ 
/min/1.73 m2)
P
Number of patients 319 (72.67%) 120 (27.33%) —
Mean follow-up [months] 39.82 ± 0.6 38.12 ± 1.1 0.141
Age 66.55 ± 0.6 73.53 ± 0.8 < 0.001
Female sex 73 (22.9%) 31 (25.8%) 0.517
Hypertension 223 (69.9%) 95 (79.2%) 0.053
Dyslipidemia 201 (63.0%) 83 (69.2%) 0.229
Diabetes mellitus 101 (31.7%) 61 (50.8%) < 0.001
Insulin therapy 17 (5.3%) 22 (18.3%) < 0.001
Smoker (current and former) 194 (60.8%) 57 (47.5%) 0.012
Previous CABG 9 (2.8%) 3 (2.5%) > 0.999*
Previous PCI 170 (49.0%) 48 (52.2%) 0.587
Previous MI 157 (49.2%) 61 (50.8%) 0.763
Peripheral vascular disease 18 (5.6%) 20 (16.7%) < 0.001
Previous stroke 14 (4.4%) 7 (5.8%) 0.527
COPD 20 (6.3%) 10 (8.3%) 0.554
Statins 287 (93.8%) 106 (91.4%) 0.382
ACEIs/ARBs 234 (76.5%) 89 (76.7%) 0.956
Beta-blockers 243 (79.4%) 90 (77.6%) 0.682
Acetylsalicylic acid 299 (95.8%) 106 (89.1%) 0.008
Anticoagulation 10 (6.3%) 20 (16.7%) 0.003
Clinical presentation: 0.451
Stable angina 144 (45.1%) 59 (49.2%)
Acute coronary syndrome 175 (54.9%) 61 (50.8%)
Results are presented as number (%) or mean (± standard deviation). P values marked with asterisk (*) are calculated with Fisher’s exact test. 
ACEIs — angiotensin-converter enzyme inhibitors; ARBs — angiotensin receptor blockers; CABG — coronary artery bypass grafting; CKD 
— chronic kidney disease; COPD — chronic obstructive pulmonary disease; eGFR — estimated glomerular filtration rate; MI — myocardial 
infarction; PCI — percutaneous coronary intervention
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deferred by physiological evaluation. When assessing 
vessel-oriented outcomes, patients with eGFR < 60 
mL/min/1.73 m2 showed similar rates of TVR (5.8% vs. 
5.0% in non-CKD patients) and target vessel MI (0.8% 
vs. 1.6% in non-CKD patients) related to the vessel 
left untreated on the grounds of non-ischemic FFR or 
iFR vales, both being non-statistically significant in the 
unadjusted and adjusted analysis (Fig. 2B, C). 
Revascularization deferral based on FFR  
or iFR: Influence on patient outcomes
In the overall population, a total of 345 (78.6%) 
patients were deferred by FFR, and 94 (21.4%) 
were deferred by iFR, with a ratio between tech-
niques similar in both groups with and without 
CKD (p = 0.936). The primary endpoint occurred 
in 64 (18.6%) patients in which the lesion was 
deferred by FFR, and in 12 (12.8%) patients de-
ferred by iFR, with no differences between the 
techniques in patients with eGFR above or below 
60 mL/min/1.73 m2 (Fig. 3, Table 5). No significant 
differences in the incidence of other events were 
observed when comparing FFR and iFR deferral 
in patients with or without CKD. 
Discussion
The main findings of the present study are as 
follows: i) in patients in whom revascularization 
of coronary stenosis has been deferred accord-
ing to pressure-wire evaluation, the presence of 
CKD is associated with worse outcomes; ii) the 
excess in POCE observed in CKD patients is 
not caused by vessel-oriented events related to 
the deferred stenoses; and iii) no differences in 
outcomes were noted in CKD patients according 
to the physiological index (iFR or FFR) used in 
decision-making. 
Overall, the findings of the study support 
the safety of pressure-guidewire based deferral 
of revascularization in patients with CKD, while 
highlighting the overall higher cardiovascular risk 
and worse prognosis of these patients, compared 
with those with normal renal function. 
Table 2. Angiographic characteristics of the population. 
No CKD (eGFR > 60 mL/
min/1.73 m2)
CKD (eGFR < 60 mL/
min/1.73 m2)
P
Number of patients 319 (72.7%) 120 (27.3%) —
Number of vessels 427 (73.0%) 158 (27.0%) —
Mean of evaluated vessels  
(per patient)
1.34 ± 0.03 1.32 ± 0.05 0.990
Vessels evaluated per patient:
1 230 (72.1%) 91 (75.8%) 0.432
2 73 (22.9%) 21 (17.5%) 0.220
3 13 (4.1%) 7 (5.8%) 0.431
4 3 (0.9%) 1 (0.8%) > 0.999*
Percent of stenosis 59 ± 0.44 61 ± 0.76 0.027
Technique for deferral: 0.936
FFR 251 (78.7%) 94 (78.3%)
iFR 68 (21.3%) 26 (21.7%)
Mean FFR 0.87 (±0.003) 0.87 (±0.004) 0.435
Mean iFR 0.95 (±0.003) 0.94 (±0.005) 0.296
Vessel evaluated:
Left main 19 (4.5%) 6 (3.8%) 0.729
LAD 178 (41.7%) 64 (40.5%) 0.797
LCX 133 (31.2%) 40 (25.3%) 0.170
RCA 91 (21.3%) 43 (27.2%) 0.131
Ramus intermedius 6 (1.4%) 5 (3.2%) 0.164
Multivessel disease (≥ 3 vessels) 60 (18.8%) 26 (21.7%) 0.501
Results are presented as number (%) or mean (± standard deviation). P values marked with asterisk (*) are calculated with Fisher’s exact test. 
CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate; FFR — fractional flow reserve; iFR — instantaneous free-wave 
ratio; LAD — left anterior descendant; LCX — left circumflex artery; RCA — right coronary artery
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Figure 2. Kaplan-Meier survival plots comparing outcomes according to the presence or not of chronic kidney dis-
ease (CKD), and across CKD stages; A. Cumulative incidence of the primary endpoint (all-cause death, infarction, or 
unplanned revascularization) for the dichotomous variable CKD; B. Incidence of the primary endpoint for the different 
CKD stages; C. Incidence of target vessel revascularization for patients with or without CKD; D. Incidence of target 
vessel myocardial infarction; CI — confidence interval; eGFR — estimated glomerular filtration rate; HR — hazard 
ratio. For the individual HR of the different CKD categories (plot B), see Table 4. 
A B
C D
Figure 3. Kaplan-Meier survival plots comparing the technique used for revascularization deferral; A. Cumulative in-
cidence of the primary endpoint in patients without chronic kidney disease (CKD) (estimated glomerular filtration rate 
[eGFR] > 60 mL/min/1.73 m2) according to the technique of physiological assessment used (fractional flow reserve 
[FFR] or instantaneous wave-free ratio [iFR]); B. Cumulative incidence of the primary endpoint in patients with CKD 
(eGFR < 60 mL/min/1.73 m2); CI — confidence interval; HR — hazard ratio.
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Chronic kidney disease is an independent risk 
factor for coronary atherosclerosis and cardiovas-
cular disease [9, 12]. Although impairment of renal 
function is associated with worse outcomes after 
myocardial revascularization [13, 14], the causes 
for this increased event rate are unclear. As stated 
in the introduction, there is a paucity of data on 
whether physiology-guided revascularization might 
contribute to better outcomes of CKD patients by 
avoiding unneeded interventions. Patients with 
CKD were underrepresented in pivotal studies 
supporting the value of FFR and iFR. In the FAME 
and FAME II trials no exclusion criteria were es-
tablished based on renal function, but in the latter, 
the prevalence of defined CKD was less than 3% 
in the overall population. 
From a theoretical standpoint, it might be pos-
sible that the diagnostic yield of both FFR and iFR 
is impaired in patients with CKD. Endothelial and 
microvascular dysfunction are common features 
of CKD, leading to impaired coronary vasodilator 
capacity [15] and higher microcirculatory resist-
ances [16]. Coronary vasodilator dysfunction is an 
independent predictor of mortality in patients with 
CKD [17], with incremental diagnostic power over 
clinical assessment, left ventricular systolic func-
tion, and the presence of ischemia or non-viable 
myocardium. Due to this, the use of hyperemic-
dependent diagnostic methods may be inadequate 
in establishing the true hemodynamic significance 
of coronary stenoses in CKD patients. On the 
other hand, iFR has demonstrated a closer cor-
relation with coronary flow reserve (CFR) values 
than FFR. Because CFR is predictive of the risk 
of cardiovascular death regardless of CKD stage 
[18], it remains plausible that decision-making with 
FFR and iFR might be associated with differences 
in patient outcomes.
Few studies have focused on the use of phys-
iology-based coronary indices in CKD patients. 
Tebaldi et al. [16] found that patients with CKD 
were more likely to have non-ischemic values of 
FFR, this being more frequent as renal function 
worsens. Conversely, a short report (n = 42) on 
hemodialysis patients [19] showed that the optimal 
cut-off value of FFR for detection of myocardial 
Table 5. Outcomes for patients according to the technique of pressure wire used to defer treatment 
and the presence or absence of chronic kidney disease. 
Endpoint FFR deferred iFR deferred HR and 95% CI P
MACE (death, MI, or revascularization): 64 (18.6%) 12 (12.8%) 0.73 (0.39–1.35) 0.310
> 60 mL/min/1.73 m2 38 (15.1%) 8 (11.8%) 0.83 (0.39–1.77) 0.624
< 60 mL/min/1.73 m2 26 (27.7%) 4 (15.4%) 0.57 (0.20–1.65) 0.302
All-cause mortality: 25 (7.3%) 8 (8.5%) 1.30 (0.59–2.89) 0.519
> 60 mL/min/1.73 m2 12 (4.8%) 5 (7.4%) 1.67 (0.59–4.76) 0.333
< 60 mL/min/1.73 m2 13 (13.8%) 3 (11.5%) 0.94 (0.27–3.33) 0.925
Cardiovascular mortality: 8 (2.3%) 3 (3.2%) 1.48 (0.39–5.59) 0.729
> 60 mL/min/1.73 m2 2 (0.8%) 2 (2.9%) 4.15 (0.58–29.60) 0.156
< 60 mL/min/1.73 m2 6 (6.4%) 1 (3.9%) 0.62 (0.07–5.16) 0.659
MI: 16 (4.7%) 3 (3.2%) 0.87 (0.25–3.00) 0.822
> 60 mL/min/1.73 m2 12 (4.8%) 2 (2.9%) 0.74 (0.16–3.30) 0.690
< 60 mL/min/1.73 m2 4 (4.3%) 1 (3.9%) 1.36 (0.14–12.88) 0.792
Revascularization: 33 (9.6%) 4 (4.3%) 0.48 (0.17–1.35) 0.161
> 60 mL/min/1.73 m2 20 (8.0%) 3 (4.4%) 0.61 (0.18–2.05) 0.421
< 60 mL/min/1.73 m2 13 (13.8%) 1 (3.9%) 0.28 (0.04–2.16) 0.223
TVR: 21 (6.1%) 2 (2.1%) 0.39 (0.09–1.71) 0.216
> 60 mL/min/1.73 m2 14 (5.6%) 2 (2.9%) 0.62 (0.14–2.75) 0.533
< 60 mL/min/1.73 m2 7 (7.5%) 0 (0%) — —
Target vessel MI: 4 (1.2%) 2 (2.1%) 2.57 (0.46–14.24) 0.280
> 60 mL/min/1.73 m2 3 (1.2%) 2 (2.9%) 3.48 (0.58–21.03) 0.175
< 60 mL/min/1.73 m2 1 (1.1%) 0 (0%) — —
Events are shown as number (%). CI — confidence interval; FFR — fractional flow reserve; HR — hazard ratio; iFR — instantaneous wave-free 
ratio; MACE — major adverse cardiac events MI — myocardial infarction; TVR — target vessel revascularization
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ischemia (assessed with stress myocardial perfu-
sion imaging techniques) was similar to the cut-off 
value in the overall population. However, because 
those studies were transversal in nature and lacked 
clinical follow-up of their study populations, the 
clinical impact of an FFR-based treatment strategy 
remains unknown.
In our study, we observed that patients with 
an eGFR of less than 60 mL/min/1.73 m2 had 
a higher incidence of the primary endpoint (all-cause 
death, MI, or unplanned revascularization) when 
compared to patients with preserved renal function. 
Although in the adjusted analysis this association 
was not statistically significant, we could observe 
a trend (p = 0.071). This conclusion is further sup-
ported by the gradient effect that was observed in 
the staged analysis: as the renal function worsens, 
the incidence of POCE increases. We observed 
a 5% annual risk of POCE in the population with 
CKD, in contrast with a 3.6% annual risk in the 
non-CKD population. Both are comprised within 
the upper and lower limits of the incidence of 1-year 
major cardiovascular events estimated in previous 
studies of pressure wire-deferred vessels [6, 20].
This difference of POCE between CKD and 
non-CKD patients was mainly caused by an aug-
mented risk of all cause death, cardiac death, and 
unplanned revascularizations, the incidence of MI 
being similar in both groups. 
What is more relevant, even with this greater 
incidence of POCE and higher prevalence of co-
morbidities, there were no significant differences in 
vessel-oriented events (TVR or target vessel MI) 
related to the coronary artery interrogated with 
iFR or FFR. This supports our conclusion that, 
although patients with CKD are at high-risk for the 
development of cardiovascular events, deferring 
lesions according to pressure wire values is safe 
in terms of the incidence of MI or the necessity of 
unplanned revascularization in the evaluated ves-
sel. In practice, at 4 years of follow-up, only half of 
the total amount of revascularizations in patients 
with renal insufficiency were performed in the 
previously interrogated vessel, in contrast with 
69% in the non-CKD population. Furthermore, 
in CKD patients only 1 out of every 5 MIs during 
follow-up was attributable to the vessel assessed. 
Overall, these observations might reflect a wider 
progression of the disease in patients with CKD, 
not restricted to the vessel evaluated with pressure 
wire, and this leads to events related with other 
areas of the coronary tree. 
In the sub-analysis regarding the technique 
used for physiological assessment, we conclude 
that, despite obvious limitations, the use of iFR to 
defer the treatment of intermediate coronary ste-
nosis is associated with similar outcomes to those 
with the use of FFR, irrespective of the presence 
or absence of renal insufficiency. However, in this 
cohort the decision of whether to perform iFR or 
FFR was at the operator’s discretion, and therefore 
we cannot exclude the occurrence of selection bias. 
Additionally, the sample number did not provide 
enough power to compare both techniques in dif-
ferent CKD stages. In order to precisely address 
the potential role of non-hyperemic indexes against 
FFR in more advanced renal insufficiency, a rand-
omized study between both techniques is needed. 
Limitations of the study 
This study has various limitations. First, it is 
a single-center, retrospective, and observational 
study, and even if the results appear to be con-
sistent, they should be considered as hypothesis-
-generating until further prospective randomized 
data becomes available. Second, eGFR estimated 
via creatinine levels could not be a reliable estima-
tor of the baseline renal function in some cases. 
Although operators are discouraged to perform 
coronary angiography in the setting of acute renal 
failure, there was no previous data in order to 
exclude patients with recent worsening of eGFR. 
Third, the absence of randomization could have 
led to involuntary patient selection, avoiding the 
realization of angiography in patients with worse 
renal function. Fourth, because of the reduced 
number of patients with more severe CKD (eGFR 
< 30 mL/min/1.73 m2), conclusions regarding sec-
ondary outcomes or the comparison between iFR 
and FFR in this subgroup were not feasible due 
to the lack of statistical power. And fifth, because 
FFR, iFR, and eGFR are continuous variables, the 
dichotomization in cut-off points always involves 
the loss of potentially relevant data. Limitations 
regarding comparison of FFR and iFR have been 
previously discussed.
On the other hand, our study provides real-
-world information about outcomes in daily prac-
tice, and the results mentioned above can fuel 
future investigations that will help to elucidate 
the best therapeutic strategies in CKD patients. 
Conclusions 
Patients with CKD and coronary lesions de-
ferred upon pressure-wire evaluation have a higher 
risk of POCE than those with normal renal func-
tion, but these events are not related to the de-
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ferred vessel. Pressure-wire evaluation is safe in 
terms of the risk of target vessel revascularization 
or target vessel MI in this population. 
Conflict of interest: Dr. Travieso-Gonzalez, Dr. 
Casto-Mejia, Dr. Jeronimo-Baza, Dr. Perez-Vizcay-
no, Dr. Mejia-Rentería, Dr. Macaya, Dr. Tirado-
Conte, Dr. Jimenez-Quevedo, Dr. Salinas, and Dr. 
Nuñez-Gil do not have disclosures. Dr. Nombela-
Franco has served as proctor for Abbott and has re-
ceived speaker honoraria from Edwards Lifescienc-
es. Dr. Fernandez-Ortiz is a speaker at educational 
events funded by Medtronic, Biotronik, Biosensor, 
and Bayer. Dr. Escaned is a speaker and consult-
ant for Abbott, Boston Scientific, and Phillips and 
has received personal fees from Phillips Volcano, 
Boston Scientific, and Abbott/St. Jude Medical. Dr. 
Gonzalo is a speaker at educational events funded 
by Abbott and Boston Scientific.
References
1. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow re-
serve versus angiography for guiding percutaneous coronary in-
tervention. N Engl J Med. 2009; 360(3): 213–224, doi: 10.1056/
NEJMoa0807611, indexed in Pubmed: 19144937.
2. Davies JE, Sen S, Dehbi H-M, et al. Use of the Instantaneous 
Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl 
J Med. 2017; 376: 1824–1834.
3. Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instanta-
neous Wave-free Ratio versus Fractional Flow Reserve to Guide 
PCI. N Engl J Med. 2017; 376(19): 1813–1823, doi: 10.1056/NEJ-
Moa1616540, indexed in Pubmed: 28317438.
4. Lee HS, Lee JM, Nam CW, et al. Consensus document for inva-
sive coronary physiologic assessment in Asia-Pacific countries. 
Cardiol J. 2019; 26(3): 215–225, doi: 10.5603/CJ.a2019.0054, in-
dexed in Pubmed: 31225632.
5. Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to 
determine the appropriateness of angioplasty in moderate coronary 
stenosis: a randomized trial. Circulation. 2001; 103(24): 2928–2934, 
doi: 10.1161/01.cir.103.24.2928, indexed in Pubmed: 11413082.
6. Escaned J, Ryan N, Mejía-Rentería H, et al. Safety of the deferral 
of coronary revascularization on the basis of instantaneous wa-
ve-free ratio and fractional flow reserve measurements in stable 
coronary artery disease and acute coronary syndromes. JACC 
Cardiovasc Interv. 2018; 11(15): 1437–1449, doi: 10.1016/j.
jcin.2018.05.029, indexed in Pubmed: 30093050.
7. Sugiyama T, Kimura S, Ohtani H, et al. Impact of chronic kidney 
disease stages on atherosclerotic plaque components on optical 
coherence tomography in patients with coronary artery disease. 
Cardiovasc Interv Ther. 2017; 32(3): 216–224, doi: 10.1007/
s12928-016-0408-y, indexed in Pubmed: 27339299.
8. Bundy JD, Chen J, Yang W, et al. Risk factors for progression 
of coronary artery calcification in patients with chronic kidney 
disease: The CRIC study. Atherosclerosis. 2018; 271: 53–60, 
doi: 10.1016/j.atherosclerosis.2018.02.009, indexed in Pubmed: 
29459266.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and 
the risks of death, cardiovascular events, and hospitalization. 
N Engl J Med. 2004; 351(13): 1296–1305, doi: 10.1056/NEJ-
Moa041031, indexed in Pubmed: 15385656.
10. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as 
a predictor of cardiovascular outcomes and mortality in elder-
ly individuals. J Am Coll Cardiol. 2003; 41(8): 1364–1372, doi: 
10.1016/s0735-1097(03)00163-3, indexed in Pubmed: 12706933.
11. Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice 
guidelines for chronic kidney disease: Evaluation, classification, 
and stratification. Am J Kidney Dis. 2002; 39: S1–S266.
12. Pereg D, Tirosh A, Shochat T, et al. Mild renal dysfunction asso-
ciated with incident coronary artery disease in young males. Eur 
Heart J. 2008; 29(2): 198–203, doi: 10.1093/eurheartj/ehm525, 
indexed in Pubmed: 18079138.
13. Milojevic M, Head SJ, Mack MJ, et al. The impact of chronic 
kidney disease on outcomes following percutaneous coronary 
intervention versus coronary artery bypass grafting in patients 
with complex coronary artery disease: five-year follow-up of 
the SYNTAX trial. EuroIntervention. 2018; 14(1): 102–111, doi: 
10.4244/EIJ-D-17-00620, indexed in Pubmed: 29155387.
14. Best P, Lennon R, Ting H, et al. The impact of renal insufficiency 
on clinical outcomes in patients undergoing percutaneous coro-
nary interventions. J Am Coll Cardiol. 2002; 39(7): 1113–1119, 
doi: 10.1016/s0735-1097(02)01745-x.
15. Chade AR, Brosh D, Higano ST, et al. Mild renal insufficiency is 
associated with reduced coronary flow in patients with non-ob-
structive coronary artery disease. Kidney Int. 2006; 69(2): 266–
–271, doi: 10.1038/sj.ki.5000031, indexed in Pubmed: 16408115.
16. Tebaldi M, Biscaglia S, Fineschi M, et al. Fractional Flow Re-
serve Evaluation and Chronic Kidney Disease: Analysis From 
a Multicenter Italian Registry (the FREAK Study). Catheter 
Cardiovasc Interv. 2016; 88(4): 555–562, doi: 10.1002/ccd.26364, 
indexed in Pubmed: 26717890.
17. Murthy VL, Naya M, Foster CR, et al. Coronary vascular dys-
function and prognosis in patients with chronic kidney disease. 
JACC Cardiovasc Imaging. 2012; 5(10): 1025–1034, doi: 
10.1016/j.jcmg.2012.06.007, indexed in Pubmed: 23058070.
18. Charytan DM, Skali H, Shah NR, et al. Coronary flow reserve is 
predictive of the risk of cardiovascular death regardless of chro-
nic kidney disease stage. Kidney Int. 2018; 93(2): 501–509, doi: 
10.1016/j.kint.2017.07.025, indexed in Pubmed: 29032954.
19. Hirose K, Chikamori T, Hida S, et al. Application of pressure-
-derived myocardial fractional flow reserve in chronic hemo-
dialysis patients. J Cardiol. 2018; 71(1): 52–58, doi: 10.1016/j.
jjcc.2017.05.007, indexed in Pubmed: 29183566.
20. Sen S, Ahmad Y, Dehbi HM, et al. Clinical events after defer-
ral of LAD  revascularization following physiological  corona-
ry  assessment. J Am Coll Cardiol. 2019; 73(4): 444–453, doi: 
10.1016/j.jacc.2018.10.070, indexed in Pubmed: 30704577.
10 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
